Last reviewed · How we verify

NCT06739850

Identification of Risk Phenotypes for Sarcopenia Using DXA WBC, Anthropometric and MA Among Young Adults

Active, enrolled Last updated 18 December 2024
What this trial tests

trial testing Identification of Risk Phenotypes of Sarcopenia in Sarcopenia in 221 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
28 February 2024
Primary endpoint
31 May 2024
1 March 2025

Quick facts

Lead sponsorSuperior University
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment221
Start date28 February 2024
Primary completion31 May 2024
Estimated completion1 March 2025
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Superior University

Who can join

Adults 15 to 35, any sex, with Sarcopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This cross-sectional study aims to identify risk phenotypes for sarcopenia among young adults using Dual-energy X-ray Absorptiometry (DXA) for whole-body composition analysis, along with anthropometric and musculoskeletal assessments. Sarcopenia, characterized by the loss of muscle mass and strength, is a growing concern, particularly among the aging population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sarcopenia

Currently open trials in the same condition.

Other Superior University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06739850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing